How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals. [Review] [27 refs]

  • van Roey J. von Schoen-Angerer T. Ford N. Calmy A
  • van Roey J
  • von Schoen-Angerer T
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries. Four late-stage investigational new drugs - rilpivirine, etravirine, raltegravir and maraviroc - show potential to improve antiretroviral therapy. However, a number of issues could limit their use in developing countries, including dose selection, treatment strategy, combination with other drugs, use in specific populations and reliance on expensive tests. Key research questions relevant for developing countries need to be answered early in the drug development process to ensure maximum benefit for the majority. [References: 27]

Author-supplied keywords

  • *Anti-Retroviral Agents/tu [Therapeutic Use]
  • *Developing Countries
  • *Retroviridae Infections/dt [Drug Therapy]
  • 0 (Anti-Retroviral Agents)
  • Anti-Retroviral Agents/ad [Administration & Dosage
  • Dose-Response Relationship
  • Drug
  • Drug Design
  • Humans
  • Retroviridae Infections/ep [Epidemiology]
  • Retroviridae Infections/vi [Virology]

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • A. van Roey J. von Schoen-Angerer T. Ford N. Calmy

  • Jens van Roey

  • Tido von Schoen-Angerer

  • Nathan Ford

  • Alexandra Calmy

  • T von Schoen Angerer

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free